Clinical Trials Logo

Clinical Trial Summary

● the investigators aims to study the impact of using drug coated balloon in coronary artery bifurcation lesions on the procedural success rate & short-term MACE.


Clinical Trial Description

Study Design: A prospective study. Patients who met the inclusion criteria will be enrolled in our study will be subdivided into 2 groups :- Group A: patient Who will undergo conventional provisional stenting using standard technique with plain balloon angioplasty Group B: patient Who will undergo provisional stenting using Drug coated balloon The patients will be randomly assigned for each group using a computer randomizing software application. Both group with pass 3 stages: - Pre-procedural Interventional procedure Post -procedural Pre- procedural History taking: Age & sex. Family history. Smoking status. Medical history including hypertension (HTN), diabetes mellitus (DM), renal impairment, etc. Previous history of coronary artery disease, myocardial infarctions (MI), revascularization procedures Medical treatment and any significant history of allergy Previous intervention history regarding (site, type, diameter and length of the stent , complications and TIMI flow ) if available General &Physical examination: with special emphasis on vital data, decubitus ,lung osculation and peripheral pulsation Laboratory investigations: Including kidney function, complete blood count, and High sensitive troponin in case of acute coronary syndrome Echocardiography will be done routinely for all patients with special emphasis on ejection fraction (to be assessed by modified Simpson's method), left ventricular dimensions, resting segmental wall motion abnormalities (RSWMAs). Interventional procedure. Angiographic analysis. Serial coronary angiography will be performed at baseline (before and after intervention) and angiograms will be obtained in multiple views after intra-coronary nitrate if coronary spasm is suspected. coronary angiograms will be digitally recorded and analyzed by experienced personnel using a validated offline quantitative angiographic system and the following data will be collected: - Bifurcation lesion distribution: Left main artery bifurcation Left anterior descending artery/diagonal bifurcation Left circumflex artery/obtuse marginal bifurcation Right coronary artery/posterolateral branch Medina classification the investigators will use Medina classification for coronary bifurcation lesion in which recording any narrowing more than 50% in each of the three arterial segments of the bifurcation in the following order: proximal main vessel (PMV). Distal main branch (DMV). Side branch (SB) (1) is used to indicate the presence of a significant stenosis and (0) the absence of stenosis Main vessel Proximal reference diameter (mm) Distal reference diameter (mm) Mean reference diameter (mm) Minimal lumen diameter (mm) Percentage diameter stenosis (%)) Lesion length (mm) Angiographic restenosis (%) Side branch Reference diameter (mm) Minimal lumen diameter (mm) Percentage diameter stenosis (%) Lesion length (mm) Type of drug-eluting stents Sirolimus-eluting stents Everolimus-eluting stents Zotrolimus-eluting stents Biolimus A9-eluting stent Number of stent/drug-eluting balloon used Stent/drug-eluting balloon size (mm) Stent/drug-eluting balloon length (mm) Maximum balloon size (mm) Maximum inflation pressure (atmosphere) other coronary lesions Intervention 1. wire both branches, MV and SB, with two coronary guide wires. 2. Main branch pre-dilation 3. Side branch pre-dilation using (ordinary balloon in group "A" and Drug coated balloon in group "B" for the side branch) 4. Main vessel stenting 5. Proximal optimization technique (POT) of the main vessel stent The following data will be recorded: - 1. Inflation time (Seconds.) 2. Inflation pressure (atmospheric pressure.) 3. Diameter of the stent after inflation 4. Time of the procedure After Intervention 1) Reference luminal diameter (mm) 2) Minimal luminal diameter in stent (mm) 3) Minimal luminal diameter in lesion (mm) 4) lesion success (attainment of >50% residual stenosis of the target lesion, as measured by quantitative coronary angiographic analysis) 5) procedure success (attainment of a final lesion success and no major angiographic complications as dissection or perforation ). Post-procedural Medications will be prescribed according to 2018 ESC myocardial revascularization guidelines. Patients will be assessed for immediate outcomes: lesion success attainment of >50% residual stenosis of the target lesion, as measured by quantitative coronary angiographic analysis procedure success attainment of a final lesion success and no major complication as :- A. Perforation with or without tamponade B. vascular access complications C. myocardial infarction D. contrast-induced nephropathy E. urgent coronary artery bypass grafting F. urgent repeat PCI G. Death. Patients be assessed and monitor for 24 hours after the procedure and in the outpatient clinic after 6 months. Follow up clinically after 6 months for MACEs Study end points. Primary end point target is 6-month follow-up for:- MACEs (major adverse cardiac events) defined as :- 1. Death 2. Non-fatal myocardial infarction 3. Target lesion re-vascularization (TLR) "defined as any clinically driven intervention (surgical or percutaneous) to the target lesion or any segment of the epicardial coronary artery containing the target lesion" 4. Stroke Improvement or recurrence of symptoms (chest pain and dyspnea) Symptomatic patients will undergo coronary angiography and those who has no symptoms with undergo functional assessment using either (High dose dobutamine echo or Myocardial perfusion imaging ) Secondary end points included: lesion success procedure success ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05872074
Study type Interventional
Source Ain Shams University
Contact Ahmed M Hassan, MSc
Phone 01002464361
Email Am.hassan88@gmail.com
Status Recruiting
Phase N/A
Start date October 4, 2023
Completion date October 11, 2023

See also
  Status Clinical Trial Phase
Completed NCT01900691 - Removal of the Evolution® Esophageal Stent - Fully Covered N/A
Enrolling by invitation NCT01172158 - SMS Reminder for Forgotten Ureteral Stents N/A
Completed NCT04115696 - Biodegradable Stent Implantation in Biliary Benign Strictures.
Completed NCT01124942 - MGuard Stent in ST-elevation Myocardial Infarction N/A
Completed NCT02811796 - Angio-based Fractional Flow Reserve to Predict Adverse Events After Stent Implantation
Recruiting NCT01997242 - The Surgery After Stenting (SAS) Registry N/A
Completed NCT01056744 - Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents Phase 4
Completed NCT00691314 - Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis N/A
Completed NCT00180479 - SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) Phase 3
Completed NCT03521700 - Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement Phase 2/Phase 3
Active, not recruiting NCT01160900 - FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization. Phase 3
Completed NCT00937573 - Xience V at Wake Forest University Baptist Medical Center (WFUBMC) N/A
Recruiting NCT00637104 - European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent Phase 2/Phase 3
Completed NCT03989557 - Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms Phase 4
Withdrawn NCT03375411 - First-in-Man Study: Safety and Efficacy of INC-1 Bare Metal Stent in the Novo Coronary Lesions. N/A
Completed NCT01962168 - Evolution® Biliary Stent System Clinical Study N/A
Completed NCT00769938 - WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) Phase 4
Completed NCT05556668 - Percutaneous Biodegradable Biliary Stents for the Treatment of Benign Biliary Strictures.
Terminated NCT03119012 - P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold Phase 4